CIK 1579853
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2018-Q1. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 55.24% | 12 |
| Unclassified | 35.78% | 9 |
| Food & Staples Retailing | 4.52% | 1 |
| Distributors | 2.89% | 1 |
| Health Care Equipment & Supplies | 1.57% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | MRK | Merck & Co., Inc. | Health Care | 18.82% |
| 2 | SNY | Sanofi | Health Care | 8.87% |
| 3 | MYLAN NV | Unclassified | 8.69% | |
| 4 | CIGNA CORPORATION | Unclassified | 8.53% | |
| 5 | AZN | Astrazeneca PLC | Health Care | 7.23% |
| 6 | REGN | REGENERON PHARMACEUTICALS, INC. | Health Care | 5.20% |
| 7 | RADIUS HEALTH INC | Unclassified | 5.15% | |
| 8 | GILD | GILEAD SCIENCES, INC. | Health Care | 4.56% |
| 9 | CVS | CVS HEALTH Corp | Consumer Staples | 4.52% |
| 10 | ALLERGAN PLC | Unclassified | 4.20% |
15/24 names classified · sector 64.2% of weight · industry 64.2% · mkt cap 48.1%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 64.2% of the book is sector-classified (unclassified names shown, never dropped).
Only 43% of book weight classified — the grid is NOT representative of the whole book.
Classified: 42.9% of book weight (10/16 names) · unclassified 57.1%: , SNY, AZN, ANAB, PTGX, PRTA. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | MRKMERCK & CO INC | 107,434 | $7M | 18.8% | TRIM −62% |
| 2 | SNYSANOFI SA | 76,836 | $3M | 8.9% | TRIM −85% |
| 3 | MYLAN NV | 83,370 | $3M | 8.7% | TRIM −83% |
| 4 | CIGNA CORPORATION | 17,392 | $3M | 8.5% | TRIM −81% |
| 5 | AZNASTRAZENECA PLC | 71,400 | $3M | 7.2% | TRIM −91% |
| 6 | REGNREGENERON PHARMACEUTICALS | 5,220 | $2M | 5.2% | TRIM −92% |
| 7 | RADIUS HEALTH INC | 60,521 | $2M | 5.1% | NEW |
| 8 | GILDGILEAD SCIENCES INC | 22,300 | $2M | 4.6% | NEW |
| 9 | CVSCVS HEALTH CORP | 24,330 | $2M | 4.5% | TRIM −80% |
| 10 | ALLERGAN PLC | 8,723 | $1M | 4.2% | TRIM −91% |
| 11 | ALDER BIOPHARMACEUTICALS INC | 85,558 | $1M | 3.9% | TRIM −90% |
| 12 | ANABANAPTYSBIO INC | 15,970 | $1M | 3.3% | TRIM −37% |
| 13 | MCKMCKESSON CORP | 7,500 | $1M | 2.9% | NEW |
| 14 | TBPHTHERAVANCE BIOPHARMA INC | 27,397 | $621,000 | 1.8% | TRIM −85% |
| 15 | MDXGMIMEDX GROUP INC | 85,050 | $543,000 | 1.6% | TRIM −91% |
| 16 | ALNYALNYLAM PHARMACEUTICALS INC | 5,425 | $534,000 | 1.5% | NEW |
| 17 | ENDOLOGIX INC | 91,422 | $517,000 | 1.5% | TRIM −93% |
| 18 | CONCERT PHARMACEUTICALS INC | 29,821 | $502,000 | 1.4% | TRIM −85% |
| 19 | ARENA PHARMECEUTICALS INC | 11,123 | $485,000 | 1.4% | TRIM −91% |
| 20 | TGTXTG THERAPEUTICS INC | 31,594 | $415,000 | 1.2% | TRIM −93% |
| 21 | PTGXPROTAGONIST THERAPEUTICS INC | 61,304 | $412,000 | 1.2% | TRIM −65% |
| 22 | FOAMIX PHARMACEUTICALS LTD | 67,429 | $338,000 | 1.0% | NEW |
| 23 | UTHRUnited Therapeutics Corp. | 2,625 | $297,000 | 0.9% | TRIM −94% |
| 24 | PRTAPROTHENA CORP PLC | 17,090 | $249,000 | 0.7% | NEW |
Where this firm's principals came from and which firms its alumni went on to found.
